We are excited to announce the successful exit of our portfolio company adivo, which we have supported from the very beginning as one of the first investors.
The company is a leader in discovering species-specific therapeutic antibodies for pets and announced that it has entered into an agreement to be acquired by Zoetis Inc. (NYSE:ZTS), the global leader in animal health.
This exit is the result of an ongoing collaboration in canine antibody drug discovery since 2021, which was expanded to include adivo’s novel feline antibody library in 2022. In addition to successful research collaborations, adivo’s proprietary drug development activities led to a promising portfolio of antibody drug candidates in oncology and inflammatory diseases with a first-in-patient study to treat canine solid tumors initiated earlier in 2023.
adivo will serve as one of Zoetis’ innovation hubs for antibody drug discovery with its headquarters and more than 1,000 m2 of lab space in Puchheim, Munich.
Big congratulations to the founding team Kathrin Ladetzki-Baehs, Markus Waldhuber and Philipp Baer – we wish you the greatest possible success!
More information in the press release under the following Link
More about adivo
